KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 128 filers reported holding KYMERA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,942,154 | +78.9% | 433,573 | +141.0% | 0.00% | +33.3% |
| Q1 2024 | $7,233,507 | +61.0% | 179,938 | +1.9% | 0.00% | +50.0% |
| Q4 2023 | $4,493,690 | +70.4% | 176,500 | -7.0% | 0.00% | +100.0% |
| Q3 2023 | $2,637,289 | -49.6% | 189,733 | +7.5% | 0.00% | -66.7% |
| Q2 2023 | $5,230,526 | 0.0% | 176,528 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $5,230,526 | +16.7% | 176,528 | -1.7% | 0.00% | +50.0% |
| Q4 2022 | $4,481,992 | -99.9% | 179,567 | +7.2% | 0.00% | 0.0% |
| Q3 2022 | $3,647,453,000 | -4.7% | 167,545 | -13.8% | 0.00% | 0.0% |
| Q2 2022 | $3,826,240,000 | -79.0% | 194,324 | -54.8% | 0.00% | -75.0% |
| Q1 2022 | $18,207,883,000 | +7.8% | 430,243 | +61.7% | 0.01% | +33.3% |
| Q4 2021 | $16,891,578,000 | +8.0% | 266,051 | -0.1% | 0.01% | 0.0% |
| Q3 2021 | $15,641,817,000 | +14.4% | 266,289 | -5.6% | 0.01% | 0.0% |
| Q2 2021 | $13,678,893,000 | – | 282,039 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,350,422 | $159,710,097 | 16.82% |
| Aquilo Capital Management, LLC | 328,743 | $9,812,979 | 9.46% |
| BVF INC/IL | 5,161,801 | $154,079,760 | 4.32% |
| Redmile Group, LLC | 1,579,275 | $47,141,359 | 2.85% |
| Deer Management Co. LLC | 415,895 | $12,414,466 | 2.55% |
| Artal Group S.A. | 3,005,610 | $89,717,459 | 2.29% |
| Baker Brothers Advisors | 5,995,928 | $178,978,451 | 2.29% |
| Avoro Capital Advisors LLC | 3,888,888 | $116,083,307 | 1.55% |
| Checkpoint Capital L.P. | 82,000 | $2,447,700 | 1.48% |
| Deep Track Capital, LP | 1,500,000 | $44,775,000 | 1.34% |